| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-09-12 | Macrogenics (USA - MD) Takeda Pharmaceutical (Japan) | MGD010 | development - commercialisation | Autoimmune diseases | Termination of an agreement | |
| 2016-09-08 | Tokai Pharmaceuticals (USA - MA) | restructuring |
Cancer - Oncology | Restructuring | ||
| 2016-09-07 | Progenics Pharmaceuticals (USA - NY) | nomination |
Cancer - Oncology | Nomination | ||
| 2016-09-07 | BiolineRx (Israel) Genentech, a member of Roche Group (USA - CA - Switzerland) | BL-8040 and atezolizumab | acute myeloid leukemia (AML), solid tumors | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2016-09-07 | Catalyst Biosciences (USA - CA) | restructuring | Rare diseases - Genetic diseases - Hematological diseases | Restructuring | ||
| 2016-09-07 | Confo Therapeutics (Belgium) | chief executive officer | nomination | Nomination | ||
| 2016-09-06 | Novasep (France) | nomination |
Technology - Services | Nomination | ||
| 2016-09-05 | Erytech Pharma (France) | nomination |
Cancer - Oncology | Nomination | ||
| 2016-09-01 | Amgen (USA) Servier (France) | Procoralan® (ivabradine), S38844, omecamtiv mecarbil | chronic heart failure, stable angina, heart failure in patients with systolic dysfunction | licensing |
Cardiovascular diseases | Licensing agreement |
| 2016-09-01 | Diamyd Medical (Sweden) | nomination |
Autoimmune diseases - Metabolic diseases - Regenerative diseases | Nomination | ||
| 2016-09-01 | Novo Nordisk (Denmark) | nomination |
Metabolic diseases | Nomination | ||
| 2016-09-01 | Amgen (USA - CA) Boehringer Ingelheim (Germany) | BI 836909 (AMG420) | myeloma | product acquisition |
Cancer - Oncology | Product acquisition |
| 2016-09-01 | Halozyme Therapeutics (USA - CA) | nomination |
Cancer - Oncology | Nomination | ||
| 2016-09-01 | Vaximm (Germany) | nomination | Cancer - Oncology | Nomination | ||
| 2016-09-01 | Aduro Biotech (USA - CA) | opening of new premises | Cancer - Oncology | Opening of new premises | ||
| 2016-09-01 | Advicenne (France) | chief business officer | nomination | Rare diseases - Genetic diseases | Nomination | |
| 2016-08-31 | Veloxis Pharmaceuticals (Denmark) Veloxis Pharmaceuticals (USA | restructuring |
Transplantation - Renal diseases - Kidney diseases | Restructuring | ||
| 2016-08-31 | Recipharm (Sweden) Tillotts Pharma (Switzerland), part of Zeria group (Japan) | Asacol™ (mesalamine), Entocort™ (budesonide) | Crohn disease, ulcerative colitis | production manufacturing supply |
Production agreement | |
| 2016-08-31 | Philips (The Netherlands) Qualcomm (US - CA) | connected care solutions and services | collaboration |
Technology - Services - Medical devices | Collaboration agreement | |
| 2016-08-31 | MDxHealth (Belgium) Teva Pharmaceuticals (Israel) | SelectMDx™ for Prostate Cancer | prostate cancer | distribution |
Cancer - Oncology - Diagnostic | Distribution agreement |
